Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta … – GlobeNewswire (press release)
Nasdaq |
Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta …
GlobeNewswire (press release) CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for … Editas Medicine Out with News, Shares Drop Zacks' 7 Best Strong Buys for 2018 |
